The Cleveland Clinic Innovation Accelerator

克利夫兰诊所创新加速器

• 批准号: 8573640
• 负责人: PAUL E DICORLETO
• 金额: $ 110.62万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8573640
• 关键词: Address; Area; Back; Cardiovascular system; Clinic; Clinical; Complement; Development; Devices; Diagnostic; Funding; Generations; Goals; Health; Human; Institutes; Institution; Laboratories; Medical center; Mentors; Mission; National Heart, Lung, and Blood Institute; Occupations; Ohio; Patient Care; Pediatric Hospitals; Peer Review; Research; Research Personnel; Resources; Solutions; Staging; Technology; Therapeutic; Training; Translating; Universities; Validation; abstracting; arm; base; commercialization; experience; improved; innovation; pre-clinical; programs; success; tool

DESCRIPTION (provided by applicant): Cleveland Clinic (CC) and its partners Case Western Reserve University, Cincinnati Children's Hospital Medical Center, The Ohio State University and University of Cincinnati have a longstanding commitment and documented success in transitioning laboratory and clinical innovations into dramatic improvements in patient care, CC alone, via its commercialization arm CC Innovations (CCI), has generated 53 spin-off companies and $644 million in equity financing in the past decade; however CCI has a focus on more mature programs and does not reach back into the research pipeline. Also, contributing to commercialization success of the applicant institutions has been the establishment of the state-funded Global Cardiovascular Innovation Center (GCIC) that has a mission of advancing late-stage cardiovascular innovations, i.e., "shovel ready" opportunities with rapid job creation potential. The applicant consortium has now come together to address an unmet need by proposing a new Center (Cleveland Clinic Innovation Accelerator, CCIA) with an overall goal of propelling early-stage projects forward and educating researchers to be full partners in transforming their discoveries into high-impact advances in patient care. The proposed Center will enhance and coordinate the existing resources of the five partnering institutions to advance the very strong pipeline of laboratory discoveries and technical innovations generated every year in NHLBI mission areas (over 250 NHLBI-funded projects). This application has three specifics aims: (1) To create the CCIA - a self sustainable, multi-institutional consortium focused on translating early innovations in NHLBI mission areas into advanced solutions for improving global patient care. CCIA will complement the mission of the GCIC by reaching earlier into the discovery and development pipeline in order to address the gap between discovery research and validation/pre-clinical development. (2) To select through rigorous peer-review commercially promising NHLBI funded projects that will receive funds and expert project management. Projects shall span the technology range of diagnostics, devices, therapeutics and tools. (3) To create a nationally accessible institute for educating and mentoring researchers, clinicians and developers in biomedical innovation and entrepreneurism. The Center will provide experience-based training to cultivate a growing cadre of commercially successful innovators. Generation of the CCIA will thus create a self-sustainable engine for propelling a large pipeline of NHLBI-related research discoveries into advances in human health. (End of Abstract)

描述（由申请人提供）： Cleveland Clinic (CC) and its partners Case Western Reserve University, Cincinnati Children's Hospital Medical Center, The Ohio State University and University of Cincinnati have a longstanding commitment and documented success in transitioning laboratory and clinical innovations into dramatic improvements in patient care, CC alone, via its commercialization arm CC Innovations (CCI), has generated 53 spin-off companies and $644 million in equity financing in the past十年;但是，CCI专注于更成熟的程序，并且没有回到研究管道。此外，为申请人机构的商业化成功做出贡献还是建立了由国家资助的全球心血管创新中心（GCIC）建立的，该中心的任务是促进后期心血管创新，即具有快速创造就业机会的“铲子就绪”机会。申请人联盟现在已经聚集在一起，通过提出一个新中心（克利夫兰诊所创新加速器，CCIA）来满足未满足的需求，其总体目标是推动早期阶段的项目前进，并教育研究人员成为将他们的发现转变为患者护理高影响力进步的正式合作伙伴。拟议的中心将增强和协调五个合作机构的现有资源，以促进NHLBI任务领域每年产生的实验室发现和技术创新的强大渠道（超过250个NHLBI资助的项目）。该应用程序具有三个具体目的：（1）创建CCIA-一个自我可持续的，多机构的财团，致力于将NHLBI任务领域的早期创新转化为改善全球患者护理的高级解决方案。 CCIA将通过较早地进入发现和开发管道，以解决发现研究与验证/临床前开发之间的差距，从而补充GCIC的任务。 （2）通过严格的同行评估商业上有希望的NHLBI资助的项目，这些项目将获得资金和专家项目管理。项目应涵盖诊断，设备，治疗和工具的技术范围。 （3）创建一个全国可访问的研究所，以教育和指导研究人员，临床医生和开发人员生物医学创新和企业家主义。该中心将提供基于经验的培训，以培养越来越多的商业成功创新者干部。因此，CCIA的产生将创建一个可自我维护的引擎，以将大量与NHLBI相关的研究发现促进人类健康的进步。 （抽象的结尾）